This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arastéh, K. Articles by Hannah, A. Search for Related Content PubMed PubMed Citation Articles by Arastéh, K. Articles by Hannah, A.

The Role of Vascular Endothelial Growth Factor (VEGF) in AIDS-Related Kaposi's Sarcoma

^a Auguste-Viktoria-Krankenhaus, Berlin, Germany; ^b SUGEN, Inc., South San Francisco, California, USA

Correspondence: Keikawus Arastéh, M.D., Auguste-Viktoria-Krankenhaus, II. Innere Abteilung, Rubensstrasse 125, D-12157 Berlin, Germany. Telephone: 011-49-30-79-03-2609; Fax: 011-49-30-79-03-2005; e-mail: arasteh{at}avk.b.shuttle.de

Kaposi's sarcoma (KS) is the most common neoplasm associated with human immunodeficiency virus-1 (HIV-1) infection. KS involves the skin and mucous membranes as well as other organs and can lead to tumor-associated edema and ulcerations. Despite therapy with highly active antiviral agents, most patients with HIV-1-related KS eventually develop disseminated disease. In the treatment of KS, a strong rationale exists for the use of agents that inhibit vascular endothelial growth factor (VEGF). Angiogenesis appears to be an important feature of this disease, and recent experimental studies have demonstrated the role of VEGF and its receptors in the pathogenesis of KS. Thus, therapeutic agents that target the VEGF pathway may be an effective strategy in reducing the tumor growth and edema associated with KS. Phase I study results with SU5416, a synthetic low molecular-weight inhibitor of the VEGF-Flk-1/KDR receptor tyrosine kinase, demonstrate that this agent is well tolerated.

Preliminary results show that in a majority of patients with autoimmune deficiency syndrome (AIDS)-related disease, SU5416 clearly has biological activity (it flattens, shrinks, or dissolves lesions and reduces or resolves edema) or stabilizes the disease. Angiogenesis inhibition with SU5416 is a promising therapeutic approach in treating patients with KS, and further clinical evaluation is currently under way.

Key Words. AIDS-related Kaposi's sarcoma • VEGF • VEGF-Flk-1/KDR receptor • Angiogenesis • Angiogenesis inhibitor • Phase I clinical studies

This article has been cited by other articles:

				M. Zangari, E. Anaissie, A. Stopeck, A. Morimoto, N. Tan, J. Lancet, M. Cooper, A. Hannah, G. Garcia-Manero, S. Faderl, et al. Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma Clin. Cancer Res., January 1, 2004; 10(1): 88 - 95. [Abstract] [Full Text] [PDF]

				S. I. Resto-Ruiz, M. Schmiederer, D. Sweger, C. Newton, T. W. Klein, H. Friedman, and B. E. Anderson Induction of a Potential Paracrine Angiogenic Loop between Human THP-1 Macrophages and Human Microvascular Endothelial Cells during Bartonella henselae Infection Infect. Immun., August 1, 2002; 70(8): 4564 - 4570. [Abstract] [Full Text] [PDF]

				R. Masood, J. Cai, A. Tulpule, T. Zheng, A. Hamilton, S. Sharma, B. M. Espina, D. L. Smith, and P. S. Gill Interleukin 8 Is an Autocrine Growth Factor and a Surrogate Marker for Kaposi's Sarcoma Clin. Cancer Res., September 1, 2001; 7(9): 2693 - 2702. [Abstract] [Full Text] [PDF]